Psychedelic psilocybin therapy for depression granted Breakthrough Therapy status by FDA

The FDA has given psilocybin therapy for treatment-resistant depression a Breakthrough Therapy status. This classification suggests the treatment has demonstrated significant potential in early clinical evidence, allowing the FDA to assist and expedite subsequent development and review processes.